Close

Anti-EGFRvIII scFv h(CD3ζ) CART, pCDCAR1 (CAR-T-1-M315-Z)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-EGFRvIII chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human EGFRvIII. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EGFRvIII antibody linked to CD3-zeta signaling domains. And the vector product was designed for the treatment of glioma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • EGFRvIII
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Glioma
  • Generation
  • First
  • Vector Name
  • pCDCAR1
  • Vector Length
  • 8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • scFv-CD3ζ
  • Discription of Signaling Cassetes
  • CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta,which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • RAbDMvIII
  • Host
  • Human
  • Target Species
  • Human
  • Gene Name
  • Epidermal Growth Factor Receptor
  • Synonyms
  • EGFR;EGFR; Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor; Receptor Tyrosine-Protein Kinase ErbB-1; Erb-B2 Receptor Tyrosine Kinase 1; Proto-Oncogene C-ErbB-1; EC 2.7.10.1; ERBB1; ERBB; HER1; Epidermal Growth Factor Receptor (Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog); Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog (Avian);

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
CAR scFv data ELISA

Fig.1 Calibration curve of the binding of RAbDMvIII and RAbvIII recombinant antibodies to coated EGFRvIII in the ELISA.

CAR Construction : Latest CAR Construction

Fig.1 Calibration curve of the binding of RAbDMvIII and RAbvIII recombinant antibodies to coated EGFRvIII in the ELISA.

The concentration range for RAbDMvIII and RAbvIII was 20 to 0.02 ug/ml (x axis) and the absorbance was read at 450 nm (Y axis). The assay was analyzed twice.

Gupta, P., Han, S. Y., Holgado-Madruga, M., Mitra, S. S., Li, G., Nitta, R. T., & Wong, A. J. (2010). Development of an EGFRvIII specific recombinant antibody. BMC biotechnology, 10(1), 1-13.

CAR scFv data FCM

Fig.2 NIH3T3 and HC2 cells were mixed in a 1:1 ratio prior to staining with RAbDMvIII revealing distinct identification of an EGFRvIII cell population.

CAR Construction : Latest CAR Construction

Fig.2 NIH3T3 and HC2 cells were mixed in a 1:1 ratio prior to staining with RAbDMvIII revealing distinct identification of an EGFRvIII cell population.

The dot blot (left panel) represents human-IgG1 isotype control.

Gupta, P., Han, S. Y., Holgado-Madruga, M., Mitra, S. S., Li, G., Nitta, R. T., & Wong, A. J. (2010). Development of an EGFRvIII specific recombinant antibody. BMC biotechnology, 10(1), 1-13.

CAR scFv data ELISA

Fig.3 Affinity determination of RAbDMvIII by Saturation ELISA.

CAR Construction : Latest CAR Construction

Fig.3 Affinity determination of RAbDMvIII by Saturation ELISA.

Saturation ELISA shows the Scatchard plot of the binding of RAbDMvIII to EGFRvIII.

Gupta, P., Han, S. Y., Holgado-Madruga, M., Mitra, S. S., Li, G., Nitta, R. T., & Wong, A. J. (2010). Development of an EGFRvIII specific recombinant antibody. BMC biotechnology, 10(1), 1-13.

CAR scFv data FCM

Fig.4 Specificity of RAbDMvII1 by Flow cytometry.

CAR Construction : Latest CAR Construction

Fig.4 Specificity of RAbDMvII1 by Flow cytometry.

Freshly dissociated human GBM tumor stained with RAbDMvIII shows
the presence of surface EGFRvIII on 13% of cells (right panel).

Gupta, P., Han, S. Y., Holgado-Madruga, M., Mitra, S. S., Li, G., Nitta, R. T., & Wong, A. J. (2010). Development of an EGFRvIII specific recombinant antibody. BMC biotechnology, 10(1), 1-13.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-EGFRvIII scFv h(CD3ζ) CART, pCDCAR1 (CAR-T-1-M315-Z). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.